Mesoblast Presents Superior Efficacy of Remestemcel-L Over Ruxolitinib for SR-aGvHD
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Should l Buy MESO?
Source: Newsfilter
- Efficacy Comparison: At the 67th ASH Annual Meeting, Mesoblast presented an independent analysis indicating that remestemcel-L demonstrated superior complete and overall remission rates compared to ruxolitinib for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD), involving 2,732 patients, highlighting its clinical potential.
- Patient Distribution: Among the treatment groups, 644 patients received remestemcel-L while 1,349 received ruxolitinib, showcasing remestemcel-L's significant advantages in improving quality of life, which may enhance its market acceptance.
- Safety Analysis: While both therapies exhibited favorable safety profiles, the study noted that remestemcel-L showed better outcomes in hematological, cardiac, and hepatic adverse events, providing critical insights for clinical decision-making that could influence physician treatment choices.
- FDA Approval: Ryoncil®, as the first FDA-approved mesenchymal stromal cell product, particularly for children under 12 with SR-aGvHD, marks a significant advancement for Mesoblast in the field of cellular therapies, potentially opening new revenue streams for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MESO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.430
Low
35.00
Averages
35.00
High
35.00
Current: 15.430
Low
35.00
Averages
35.00
High
35.00
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio Advances Cell Therapy Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, driven by clinical breakthroughs and manufacturing milestones, indicating strong growth potential in regenerative medicine.
- CAR T-Cell Therapy Growth: The market value of CAR T-cell therapy is nearly $7 billion this year, with an 18% compound annual growth rate, suggesting that off-the-shelf platforms are eliminating logistical barriers to patient access, further driving market expansion.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, which will provide critical material for scalable cell therapy production, ensuring product consistency and reducing risks.
- Anti-Aging Treatment Prospects: By establishing a high-quality MCB, the collaboration between Avaí Bio and Austrianova will support the development of cell-based therapies targeting aging and related diseases, further advancing the clinical application of α-Klotho to meet growing market demand.
See More
Avaí Bio Advances α-Klotho Cell Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, with CAR T-cell therapy valued at nearly $7 billion this year and an 18% compound annual growth rate, indicating robust growth in the regenerative medicine sector.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has successfully initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, ensuring product consistency and safety, thereby laying the groundwork for anti-aging therapies.
- Significant Technical Advantage: The establishment of the MCB under Good Manufacturing Practices (GMP) not only reduces risks of contamination and genetic instability but also supports sustainable production, reinforcing the company's long-term strategy in the anti-aging sector.
- Successful Strategic Pivot: Following its rebranding, Avaí Bio has focused on biotechnology, leveraging strategic partnerships with Austrianova to advance both the α-Klotho anti-aging program and the Insulinova diabetes program, showcasing its innovative capabilities in cell therapy.
See More
Mesoblast Reports 1H 2026 Financial Results with Significant Revenue Growth
- Disappointing Earnings: Mesoblast's 1H 2026 GAAP EPS of -$3.11 missed expectations by $3.06, indicating significant challenges in achieving profitability amid ongoing operational hurdles.
- Revenue Surge: Despite the disappointing earnings, Mesoblast reported a staggering 1503.1% year-over-year revenue increase to $51.3 million, although it still fell short of the anticipated $54.8 million, highlighting market demand volatility.
- Ryoncil® Gross Profit Improvement: The gross profit from Ryoncil® reached $44.2 million, a substantial increase from nil in the prior year, suggesting growing market acceptance and sales potential for the product.
- Direct Selling Costs: Direct selling costs amounted to $7.7 million, which, while relatively high, indicates that the company's investments in sales and marketing are beginning to yield returns as revenue grows.
See More
Mesoblast Reports Strong H1 FY2026 Financial Results Driven by Ryoncil Launch
- Strong Financial Performance: Mesoblast reported total revenue of $51.3 million for H1 FY2026, a significant increase from $3.2 million in the prior year, indicating that the successful commercialization of Ryoncil® has driven substantial revenue growth for the company.
- Successful Ryoncil® Launch: The U.S. commercial launch of Ryoncil® generated gross sales of $57.0 million, with net revenue of $48.7 million after adjustments, and a gross profit of $44.2 million against direct selling costs of $7.7 million, reflecting strong market demand and profitability.
- Increased R&D Investment: The robust operational performance allowed the company to invest in R&D, including supporting a Phase 3 trial for chronic low back pain, aiming to enhance long-term market competitiveness by expanding Ryoncil®'s indications.
- Improved Cash Flow: As of December 31, 2025, Mesoblast had a cash balance of $130 million and secured a $125 million non-dilutive credit line, with expectations of reduced net cash spend in the future, enhancing financial flexibility to support expansion and clinical programs.
See More
Ryoncil Demonstrates High Survival Rates in Acute GVHD Treatment
- Importance of Early Intervention: Ryoncil has demonstrated high survival rates in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD), emphasizing the need for early use of Ryoncil after steroid resistance to complete the full treatment course and maximize survival chances.
- Clinical Trial Results: Among 53 patients receiving Ryoncil as ≥ third-line treatment for SR-aGvHD, 15% died before completing the full course, compared to only 2% in the Phase 3 trial as second-line treatment, highlighting the significant advantage of early intervention.
- First FDA-Approved MSC Product: Ryoncil is the first mesenchymal stromal cell product approved by the U.S. FDA for any indication and the only product approved for children under 12 with steroid-refractory acute graft-versus-host disease, marking a significant breakthrough in this field.
- Market Performance Analysis: Mesoblast shares are currently trading at $17.73, 1.8% above the 20-day simple moving average but 2.3% below the 50-day moving average, indicating short-term strength while facing medium-term resistance in the market.
See More
Mesoblast Reports Ryoncil® Treatment Data for SR-aGvHD
- Survival Rate Improvement: At the 2026 ASTCT meeting in Salt Lake City, Mesoblast presented data showing that Ryoncil® achieves high survival rates in steroid-refractory acute graft-versus-host disease (SR-aGvHD) patients, regardless of age, emphasizing the critical importance of early intervention to maximize survival chances.
- Treatment Outcome Comparison: Among 53 SR-aGvHD patients receiving Ryoncil® as ≥ third-line treatment, 15% died before completing the treatment course, compared to only 2% in the Phase 3 trial receiving it as second-line therapy, highlighting the significant advantages of early treatment.
- Adult Trial Plans: Mesoblast plans to initiate a pivotal trial for second-line treatment in adults with SR-aGvHD following IRB approval, with enrollment expected to begin this quarter, and if successful, it will support label extension for Ryoncil® in adults, a market approximately three times the size of the pediatric population.
- Platform Technology Advantage: Ryoncil® is the first FDA-approved mesenchymal stromal cell product for SR-aGvHD treatment, showcasing Mesoblast's leadership in cellular therapies and laying the groundwork for future treatments of other inflammatory diseases.
See More
Avaí Bio Advances Cell Therapy Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, driven by clinical breakthroughs and manufacturing milestones, indicating strong growth potential in regenerative medicine.
- CAR T-Cell Therapy Growth: The market value of CAR T-cell therapy is nearly $7 billion this year, with an 18% compound annual growth rate, suggesting that off-the-shelf platforms are eliminating logistical barriers to patient access, further driving market expansion.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, which will provide critical material for scalable cell therapy production, ensuring product consistency and reducing risks.
- Anti-Aging Treatment Prospects: By establishing a high-quality MCB, the collaboration between Avaí Bio and Austrianova will support the development of cell-based therapies targeting aging and related diseases, further advancing the clinical application of α-Klotho to meet growing market demand.
See More
Avaí Bio Advances α-Klotho Cell Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, with CAR T-cell therapy valued at nearly $7 billion this year and an 18% compound annual growth rate, indicating robust growth in the regenerative medicine sector.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has successfully initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, ensuring product consistency and safety, thereby laying the groundwork for anti-aging therapies.
- Significant Technical Advantage: The establishment of the MCB under Good Manufacturing Practices (GMP) not only reduces risks of contamination and genetic instability but also supports sustainable production, reinforcing the company's long-term strategy in the anti-aging sector.
- Successful Strategic Pivot: Following its rebranding, Avaí Bio has focused on biotechnology, leveraging strategic partnerships with Austrianova to advance both the α-Klotho anti-aging program and the Insulinova diabetes program, showcasing its innovative capabilities in cell therapy.
See More
Mesoblast Reports 1H 2026 Financial Results with Significant Revenue Growth
- Disappointing Earnings: Mesoblast's 1H 2026 GAAP EPS of -$3.11 missed expectations by $3.06, indicating significant challenges in achieving profitability amid ongoing operational hurdles.
- Revenue Surge: Despite the disappointing earnings, Mesoblast reported a staggering 1503.1% year-over-year revenue increase to $51.3 million, although it still fell short of the anticipated $54.8 million, highlighting market demand volatility.
- Ryoncil® Gross Profit Improvement: The gross profit from Ryoncil® reached $44.2 million, a substantial increase from nil in the prior year, suggesting growing market acceptance and sales potential for the product.
- Direct Selling Costs: Direct selling costs amounted to $7.7 million, which, while relatively high, indicates that the company's investments in sales and marketing are beginning to yield returns as revenue grows.
See More
Mesoblast Reports Strong H1 FY2026 Financial Results Driven by Ryoncil Launch
- Strong Financial Performance: Mesoblast reported total revenue of $51.3 million for H1 FY2026, a significant increase from $3.2 million in the prior year, indicating that the successful commercialization of Ryoncil® has driven substantial revenue growth for the company.
- Successful Ryoncil® Launch: The U.S. commercial launch of Ryoncil® generated gross sales of $57.0 million, with net revenue of $48.7 million after adjustments, and a gross profit of $44.2 million against direct selling costs of $7.7 million, reflecting strong market demand and profitability.
- Increased R&D Investment: The robust operational performance allowed the company to invest in R&D, including supporting a Phase 3 trial for chronic low back pain, aiming to enhance long-term market competitiveness by expanding Ryoncil®'s indications.
- Improved Cash Flow: As of December 31, 2025, Mesoblast had a cash balance of $130 million and secured a $125 million non-dilutive credit line, with expectations of reduced net cash spend in the future, enhancing financial flexibility to support expansion and clinical programs.
See More
Ryoncil Demonstrates High Survival Rates in Acute GVHD Treatment
- Importance of Early Intervention: Ryoncil has demonstrated high survival rates in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD), emphasizing the need for early use of Ryoncil after steroid resistance to complete the full treatment course and maximize survival chances.
- Clinical Trial Results: Among 53 patients receiving Ryoncil as ≥ third-line treatment for SR-aGvHD, 15% died before completing the full course, compared to only 2% in the Phase 3 trial as second-line treatment, highlighting the significant advantage of early intervention.
- First FDA-Approved MSC Product: Ryoncil is the first mesenchymal stromal cell product approved by the U.S. FDA for any indication and the only product approved for children under 12 with steroid-refractory acute graft-versus-host disease, marking a significant breakthrough in this field.
- Market Performance Analysis: Mesoblast shares are currently trading at $17.73, 1.8% above the 20-day simple moving average but 2.3% below the 50-day moving average, indicating short-term strength while facing medium-term resistance in the market.
See More
Mesoblast Reports Ryoncil® Treatment Data for SR-aGvHD
- Survival Rate Improvement: At the 2026 ASTCT meeting in Salt Lake City, Mesoblast presented data showing that Ryoncil® achieves high survival rates in steroid-refractory acute graft-versus-host disease (SR-aGvHD) patients, regardless of age, emphasizing the critical importance of early intervention to maximize survival chances.
- Treatment Outcome Comparison: Among 53 SR-aGvHD patients receiving Ryoncil® as ≥ third-line treatment, 15% died before completing the treatment course, compared to only 2% in the Phase 3 trial receiving it as second-line therapy, highlighting the significant advantages of early treatment.
- Adult Trial Plans: Mesoblast plans to initiate a pivotal trial for second-line treatment in adults with SR-aGvHD following IRB approval, with enrollment expected to begin this quarter, and if successful, it will support label extension for Ryoncil® in adults, a market approximately three times the size of the pediatric population.
- Platform Technology Advantage: Ryoncil® is the first FDA-approved mesenchymal stromal cell product for SR-aGvHD treatment, showcasing Mesoblast's leadership in cellular therapies and laying the groundwork for future treatments of other inflammatory diseases.
See More
